Targeting inflammasomes for therapies

Cell therapy development programs generate encouraging pre-clinical and clinical results with the promise that these tailored therapeutics can provide a curative rather than maintenance therapy. Therapies are being developed across the spectrum from academic institutions to small and medium biotechs/biopharma as well as large pharma companies which have all invested significantly in the cell and gene therapy (CGT) field. As additional CGT therapies gain approval, specifically in solid tumors and auto-immunity, the addressable patient populations will grow requiring scaled -out/-up commercial manufacturing. Although the CGT field is experiencing significant tailwinds, challenges remain. Cell sourcing has long been considered a pain-point which is potentially compounded with the necessity to develop robust GMP manufacturing processes and appropriate analytical methods.

Cloud adoption just keeps on growing and now is the time to take control. Your enterprise cloud strategy for 2019 needs to address the broad impact of cloud use in your company. Your strategy should also cover implications for your technical processes, as well as supporting areas including finance, governance, organization, and culture.

Multi-omics approaches integrate multiple omics data generated from cancer patients to better understand the molecular and clinical features of cancer. Multi-omics technologies, including genomics, proteomics, and metabolomics, have also been included in clinical trials to understand the response to immunotherapy and the mechanisms of drug resistance.

Super-resolution microscopy techniques have facilitated imaging some of the smallest cellular structures with amazing detail and have led to key discoveries in molecular and cell biology, immunology, and neurobiology. Now, there is an increasing need to bring this level of detail to rapidly-occurring cellular events.